ripekg:evaluation/RIPEA2D330616160C50F0 |
prov:used |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA2D330616160C50F0 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:concerns |
ripekg:work/10.1111%2F1756-185x.13688Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: A randomized, double‐blind, controlled trial |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:recruitmentEndDate |
05-2017 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:recruitmentEndDateExtractionRationale |
Methods: 'This randomized, double-blind, placebo-controlled trial was conducted on patients presenting to the Rheumatology Clinic of Velayat Hospital in Qazvin, Iran, from November 2016 to May 2017.' The recruitment finish date is May 2017. |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:recruitmentStartDate |
11-2016 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:recruitmentStartDateExtractionRationale |
Methods: 'This randomized, double-blind, placebo-controlled trial was conducted on patients presenting to the Rheumatology Clinic of Velayat Hospital in Qazvin, Iran, from November 2016 to May 2017.' The recruitment start date is November 2016. |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
ripe:studyEndDateExtractionRationale |
No explicit study end date is mentioned. |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA2D330616160C50F0-human-2-2 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA2D330616160C50F0-inspectai-2-2 |